Page last updated: 2024-08-21

fluorobenzenes and Brain Ischemia

fluorobenzenes has been researched along with Brain Ischemia in 15 studies

Research

Studies (15)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (13.33)	18.2507
2000's	6 (40.00)	29.6817
2010's	7 (46.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahn, SH; Chamorro, Á; Choi, DW; Choi, MH; Hong, JM; Hwang, YH; Lee, YB; Shin, DI; Sohn, SI	1
Fujinaga, M; Hatori, A; Kumata, K; Mori, W; Nengaki, N; Ohkubo, T; Xie, L; Yamasaki, T; Zhang, MR; Zhang, Y	1
Hasegawa, Y; Kataoka, K; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Kuratsu, J; Ma, M; Nakagawa, T; Sueta, D; Toyama, K; Uekawa, K	1
Daida, H; Daimon, M; Hattori, N; Kuroki, T; Miyamoto, N; Miyauchi, K; Shimada, Y; Tanaka, R; Tanaka, Y; Ueno, Y; Urabe, T; Watanabe, M; Yamashiro, K	1
Borg, JY; Guegan-Massardier, E; Joly, B; Le Cam-Duchez, V; Menard, AL; Ozkul-Wermester, O; Triquenot-Bagan, A	1
Cho, SI; Chung, JM; Gwag, BJ; Park, UJ	1
Fehér, G; Szapáry, L	1
Bassetti, CL; Hermann, DM; Kilic, E; Kilic, U; Lüscher, TF; Matter, CM	1
Bassetti, CL; Hermann, DM; Kilic, E; Kilic, U; Wang, Z; Xing, H	1
Ahn, YM; Byun, HY; Cho, JY; Cho, SI; Chung, JM; Gwag, BJ; Im, DS; Kim, KW; Ko, SY; Kwon, HJ; Lee, HU; Lee, JY; Lee, MJ; Lee, YA; Lim, HR; Moon, HS; Noh, JH; Park, SM; Son, SJ; Won, SJ; Yoon, SH; Yun, BS	1
Herman, D; Mei, Y; Sun, S; Xing, H	1
Artru, AA; Gurevich, B; Katchko, L; Lam, AM; Merkind, V; Mueller, AL; Shapira, Y; Talmor, D	1
Artman, LD; Balandrin, MF; Brady, E; Chien, Y; Delmar, EG; George, K; Kierstead, A; Marriott, TB; Moe, ST; Mueller, AL; Newman, MK; Raszkiewicz, JL; Sanguinetti, EL; van Wagenen, BC; Wells, D	1
Dawson, LA; Djali, S; Galandak, J	1
Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Laufs, U; Nickenig, G	1

Reviews

2 review(s) available for fluorobenzenes and Brain Ischemia

Article	Year
Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug news & perspectives, 2010, Volume: 23, Issue:9 Topics: Animals; Antioxidants; Benzoates; Brain Ischemia; Drug Delivery Systems; Fluorobenzenes; Humans; meta-Aminobenzoates; Neuroprotective Agents; Receptors, N-Methyl-D-Aspartate; Salicylates; Spin Trapping; Stroke; Time Factors	2010
NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Annals of the New York Academy of Sciences, 1999, Volume: 890 Topics: Adolescent; Adult; Animals; Brain Ischemia; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Learning; Male; Neuroprotective Agents; Propylamines; Receptors, N-Methyl-D-Aspartate; Stroke	1999

Trials

2 trial(s) available for fluorobenzenes and Brain Ischemia

Article	Year
Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial. Trials, 2018, Jul-13, Volume: 19, Issue:1 Topics: Brain Ischemia; Clinical Trials, Phase II as Topic; Disability Evaluation; Double-Blind Method; Endovascular Procedures; Fluorobenzenes; Humans; meta-Aminobenzoates; Multicenter Studies as Topic; Neuroprotective Agents; Prospective Studies; Randomized Controlled Trials as Topic; Recovery of Function; Republic of Korea; Salicylates; Stroke; Thrombectomy; Time Factors; Treatment Outcome	2018
Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke. Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:1 Topics: Aorta; Brain Ischemia; Echocardiography, Transesophageal; Embolism; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Research Design; Rosuvastatin Calcium; Stroke; Sulfonamides	2014

Article

Year

Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial.

Trials, 2018, Jul-13, Volume: 19, Issue:1

Topics: Brain Ischemia; Clinical Trials, Phase II as Topic; Disability Evaluation; Double-Blind Method; Endovascular Procedures; Fluorobenzenes; Humans; meta-Aminobenzoates; Multicenter Studies as Topic; Neuroprotective Agents; Prospective Studies; Randomized Controlled Trials as Topic; Recovery of Function; Republic of Korea; Salicylates; Stroke; Thrombectomy; Time Factors; Treatment Outcome

2018

Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke.

Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:1

Topics: Aorta; Brain Ischemia; Echocardiography, Transesophageal; Embolism; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Research Design; Rosuvastatin Calcium; Stroke; Sulfonamides

2014

Other Studies

11 other study(ies) available for fluorobenzenes and Brain Ischemia

Article	Year
Synthesis of two novel [ Organic & biomolecular chemistry, 2018, 09-26, Volume: 16, Issue:37 Topics: Animals; Brain; Brain Ischemia; Carrier Proteins; Chemistry Techniques, Synthetic; Fluorobenzenes; Hydrophobic and Hydrophilic Interactions; Mice; Positron-Emission Tomography; Radioactive Tracers; Radiochemistry; Rats; Receptors, GABA-A; Spiro Compounds; Tissue Distribution	2018
Pretreatment with rosuvastatin protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress and inflammation. Brain research, 2013, Jun-26, Volume: 1519 Topics: Animals; Brain Infarction; Brain Ischemia; Calcium-Binding Proteins; Cyclooxygenase 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ectodysplasins; Encephalitis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Glycoproteins; Microfilament Proteins; NADPH Oxidase 2; NADPH Oxidases; NF-kappa B; Nitric Oxide Synthase Type II; Oxidative Stress; Pyrimidines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Up-Regulation	2013
Involvement of Arg306 mutation in factor V gene in two young men with ischemic stroke. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:8 Topics: Anticholesteremic Agents; Arginine; Aspirin; Brain Ischemia; DNA Mutational Analysis; Factor V; Fibrinolytic Agents; Fluorobenzenes; Humans; Intracranial Thrombosis; Male; Middle Aged; Mutation; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Young Adult	2014
[Effectiveness of generic rosuvastatin in patients with ischaemic cerebrovascular disease]. Orvosi hetilap, 2012, Jun-03, Volume: 153, Issue:22 Topics: Aged; Biomarkers; Brain Ischemia; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drugs, Generic; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2012
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke, 2005, Volume: 36, Issue:2 Topics: Animals; Blotting, Western; Brain; Brain Ischemia; Enzyme Inhibitors; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ischemia; Laser-Doppler Flowmetry; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Pyrimidines; Rosuvastatin Calcium; Signal Transduction; Stroke; Sulfonamides; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator	2005
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2. Neuroscience, 2005, Volume: 134, Issue:3 Topics: Animals; Blotting, Western; Brain Infarction; Brain Ischemia; Cell Count; Dose-Response Relationship, Drug; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Laser-Doppler Flowmetry; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrimidines; Reperfusion; Rosuvastatin Calcium; Staining and Labeling; Sulfonamides; Time Factors	2005
Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2007, Volume: 27, Issue:6 Topics: Animals; Antioxidants; Aspirin; Benzoates; Brain Ischemia; Cells, Cultured; Excitatory Amino Acid Antagonists; Fluorobenzenes; Infarction, Middle Cerebral Artery; meta-Aminobenzoates; Mice; N-Methylaspartate; Oxidative Stress; Receptors, N-Methyl-D-Aspartate; Salicylates; Sulfasalazine	2007
The protective effect of rosuvastatin on ischemic brain injury and its mechanism. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2006, Volume: 26, Issue:6 Topics: Animals; Brain Ischemia; Caspase 3; Cerebral Cortex; Disease Models, Animal; Fluorobenzenes; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2006
Neuroprotective effects of NPS 846, a novel N-methyl-D-aspartate receptor antagonist, after closed head trauma in rats. Journal of neurosurgery, 1998, Volume: 88, Issue:6 Topics: Animals; Body Water; Brain; Brain Edema; Brain Ischemia; Calcium; Cerebral Hemorrhage; Fluorobenzenes; Head Injuries, Closed; Homeostasis; Injections, Intraperitoneal; Injury Severity Score; Magnesium; Necrosis; Neuroprotective Agents; Potassium; Propylamines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sodium; Specific Gravity; Time Factors; Treatment Outcome	1998
Attenuation of ischemic efflux of endogenous amino acids by the novel 5-HT(1A)/5-HT(2) receptor ligand adatanserin. Neurochemistry international, 2002, Volume: 40, Issue:3 Topics: Amino Acids; Animals; Brain Ischemia; Fluorobenzenes; Hippocampus; In Vitro Techniques; Indoles; Ligands; Male; Piperazines; Piperidines; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Antagonists; Serotonin Receptor Agonists	2002
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain research, 2002, Jun-28, Volume: 942, Issue:1-2 Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Infarction; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Endothelium, Vascular; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Mice; Mice, Inbred Strains; Neuroprotective Agents; Nitric Oxide Synthase; Pyrimidines; Reperfusion Injury; RNA, Messenger; Rosuvastatin Calcium; Stroke; Sulfonamides; Up-Regulation	2002